Articles

Neoadjuvant nivolumab plus platinum-doublet chemotherapy resulted in clinically meaningful improvement in event-free survival and pathologic complete response in patients with resectable NSCLC compared with chemotherapy alone. Read More ›

Neoadjuvant treatment of patients with resectable early-stage NSCLC with durvalumab in combination with the anti-CD73 monoclonal antibody oleclumab, the anti-NKG2A monoclonal antibody monalizumab, or the anti-STAT3 antisense oligonucleotide danvatirsen resulted in improved efficacy compared with durvalumab alone. Read More ›

The combination of canakinumab and pembrolizumab plus chemotherapy did not statistically improve efficacy as first-line treatment in patients with advanced NSCLC. Read More ›

The combination of nivolumab plus docetaxel for NSCLC in the second-line setting improved overall survival, progression-free survival, and overall response rate, despite a slightly elevated risk of toxicity. Read More ›

First-line treatment of patients with advanced NSCLC with toripalimab plus chemotherapy resulted in improved progression-free survival and overall survival compared with chemotherapy alone. Read More ›

Sugemalimab plus chemotherapy resulted in statistically significant and clinically meaningful progression-free survival and overall survival improvement compared with placebo plus chemotherapy, regardless of tumor histology or PD-L1 expression level, in patients with newly diagnosed metastatic NSCLC. Read More ›

DESTINY-Breast04 is the first trial comparing outcomes with trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients with HER2-low metastatic breast cancer treated with 1 or 2 prior lines of chemotherapy. Read More ›

The TROPiCS-02 study aims to confirm optimal treatment choice in patients with hormone receptor–positive/HER2-negative metastatic breast cancer whose disease progresses after having received endocrine therapy (ET) plus cyclin-dependent kinase (CDK)4/6 inhibitor. Read More ›

Patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer who had previously advanced on any cyclin-dependent kinase (CDK)4/6 inhibitor plus any endocrine therapy (ET) showed a substantial progression-free survival (PFS) advantage in the ribociclib-treated cohort. Read More ›

Pembrolizumab plus chemotherapy increased event-free survival compared with chemotherapy alone, highlighting the relevance of neoadjuvant pembrolizumab therapy for improving survival in patients with early triple-negative breast cancer. Read More ›